Replies to post #198451 on Biotech Values

[DewDiligence]

Keytruda bests chemo PFS/OS in first-line NSCLC with PD-L1 expression ≥50%, leading to early stop of KEYNOTE-024 trial:

http://finance.yahoo.com/news/merck-keytruda-pembrolizumab-demonstrates-superior-104500135.html